Via Scientific, the developer of the multi-omics platform Via Foundry, has successfully closed a $5 million seed funding round led by G20 Ventures and Innospark Ventures. The syndicate includes prominent Life Science and AI Angel investors such as Melissa J. Moore (former CSO of Moderna), Rob Hickey (Former EVP at DataRobot), and Janet Kosloff (Founder and former CEO of InCrowd, Inc.).
The Via Foundry platform is designed to accelerate the pace of life sciences discovery by providing pharmaceutical companies, bio-techs, and academic researchers with a comprehensive multi-omics solution. This platform allows researchers to explore novel biological insights by analyzing data across various omics disciplines, including genomics, proteomics, transcriptomics, and epigenomics, along with real-world evidence like phenotypes and clinical data.
Originally developed in the Bioinformatics Core at the University of Massachusetts Chan Medical School, Via Foundry leverages artificial intelligence (AI) to analyze large-scale, complex, and dynamic biological data. The platform enables researchers to identify patterns, associations between biological entities, relevant biomarkers, pathways, and markers of disease and physiology.
Jim Crowley, co-founder, and CEO of Via Scientific emphasized the transformative potential of their platform, stating, “From precision medicine to agriculture to climate change and beyond, Via Foundry is a living, breathing scientific ecosystem that empowers scientists to better understand and advance our collective and individual health, and the overall health of our planet’s global ecosystem.”
Alper Kucukural, co-founder CTO of Via Scientific and Associate Professor at UMass Chan Medical School, highlighted their commitment to democratizing science through cutting-edge AI technologies. The funding will be instrumental in accelerating Via Scientific’s go-to-market activities, expanding its library of bioinformatic processes, pipelines, and AI models, and growing its technology and scientific teams.
Mike Troiano, Partner at G20 Ventures, expressed that Via Scientific is a game-changer in the biopharmaceutical landscape, streamlining complex multi-omics and real-world data analyses to contribute to advancements in disease, hunger, and climate change research. Matt Fates, Partner at Innospark Ventures, underscored the compelling combination of the team’s scientific, AI, and domain expertise, along with their notable customer traction. Troiano and Fates will both join Via’s Board of Directors.
